MCIM
XFOR icon

Meadow Creek Investment Management’s X4 Pharmaceuticals XFOR Stock Holding History

Meadow Creek Investment Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$15K Buy
+39
New +$15.4K ﹤0.01% 1336

Other funds holding XFOR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Meadow Creek Investment Management's XFOR Position: Q3 2019 in Review

Meadow Creek Investment Management opened a new position in X4 Pharmaceuticals (XFOR) in Q3 2019: 39 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #1336 among its holdings.

49 funds tracked by Wall St. Rank hold XFOR as of Q3 2019.

  • Meadow Creek Investment Management held 39 shares of X4 Pharmaceuticals worth $15K as of Q3 2019.
  • X4 Pharmaceuticals was a new Meadow Creek Investment Management position in Q3 2019.
  • X4 Pharmaceuticals made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1336 holding.
  • 49 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.